I-SPY 2 TRIAL COVID-19 Pandemic Update

March 23rd, 2020

I-SPY 2 Sponsor COVID-19 Update

As of 3.23.2020

- I-SPY PMO
 - All members are available to perform their work by telecommuting. Note CRAs were already telecommuting. All team members are available by email and phone.
 - Clinical supply orders: SD-101 Needle orders are on back order. We are shipping needles from one site to another at this time to handle pt visits in the next 2 weeks. Asking sites to check drug supply and maintain sufficient inventory of critical supplies needed.
 - E-signatures (e.g. DocuSign) is preferable, if not possible, email confirmation/approval by oncologist with this copied and uploaded as source to EDC.
- I-SPY Laboratory and Repository
 - Limited staff will be handling 'Essential' collections, processing, and storage.
 - Agendia is currently staffed to handle processing
 - FedEx is currently running normal
 - UCSF Histology Lab may have limited service/longer timelines; suggest diagnostic slides (note we have noticed a delay in shipping of these samples)
- I-SPY Imaging
 - All team members are telecommuting and are available by email. Their central imaging work is not affected by telecommuting. E-signatures (e.g. DocuSign) is preferable, if not possible, email confirmation/approval by radiologist with this copied and uploaded as source to EDC.

Be aware workforce may become sick or unable to work – timelines may be stretched during this outbreak. We will communicate with the sites as this situation is fluid.

Safety Reporting for COVID-19 Infection

I-SPY 2 Safety Reporting for COVID-19 Infection

- Any AE that is suspected to be a COVID-19 infection should be reported to <u>ispy2safety@ccsainc.com</u> as soon as possible as:
 - Adverse Event of Special Interest (AESI) if not serious
 - Serious Adverse Event (SAE) if it meets criteria for seriousness
- Suspected/Confirmed COVID-19 cases are now considered AESIs/SAEs for *all arms* on the I-SPY 2 TRIAL
- SAEs and AESIs:
 - SAEs reported to CCSA within 48 hours
 - AESIs reported to CCSA within 7 business days

I-SPY 2 Safety Reporting for COVID-19 Infection

- CCSA will continue to query all events until resolution
- CCSA will also query to confirm whether or not the patient was tested for COVID-19 and what the results were
 - CCSA will track the status of all potential COVID-19 cases (i.e., suspected, tested, confirmed, negative)
 - A follow-up report should be submitted when the status changes
- For questions on safety reporting, please email ispy2safety@ccsainc.com

Suspected Cases of COVID-19

• 1 patient SAE at Georgetown; in isolation and still to be tested

I-SPY 2 Visits & Procedures

I-SPY 2 Visits & Procedures	Continue Per Protocol	Allowed modification for COVID-19 situation
Screening Activities Labs MRI MammaPrint (MP)	YES	MammaPrint: Send diagnostic specimen as may have delay with processing research formalin as this goes through a histology lab; MUST ship frozen cores needed for MP Allow clinical lab collection at external labs
Randomization and Enrollment Activities	YES	Trial is open to new accruals, recognize limitations per local site guidelines
Treatment Activities MRI	YES	Collection of concomitant medications by phone, video call
Surgery Activities MRI	YES	Pre-surgical visit by phone, video call
Safety Activities Clinical labs around tx	YES	Safety assessments by phone, video call Allow clinical lab collection at external labs
Follow-up Activities	YES (See modifications)	Follow up visit by phone, video call Follow up labs on hold In person follow-up visits, delay for 2 months unless there is an issue requiring a visit (assess by a pre-screen phone call)

I-SPY 2 MRI Updates

Timepoint	Continue Per Protocol	Allowed modification for COVID-19 situation
Pre-screening	YES	
Week 3	YES	
6 week (MRI 2.5)	Optional	6-week MRI optional and do per clinical care (MR 2.5)
Week 12/Inter regimen	YES	
Mid-AC (MRI 3.5)	NO	Mid-AC MRI do not collect at this time (MR 3.5)
Pre-surgery	YES	
Pts who have discontinued investigational therapy	NO	No MRs for patients who have discontinued investigational treatment and are on SOC

I-SPY 2 Specimens Update

Timepoint	Research Biopsy/ Clinical inter-regimen Biopsy	Research blood for plasma, serum and buffy coat	Research CPT
Pre-treatment (cannot be collected at later date)	Collect if possible or needed for MammaPrint. Ship to I-SPY lab. If not collected complete CRF.	Collect if staff available to process and freeze. Store onsite, do not ship. If not collected complete CRF.	Suspend collection Note as not collected on CRF if other blood are collected.
Early treatment (wk 3)	n/a	Collect if staff available to process and freeze. Store onsite, do not ship. If not collected plan to collect in one month.	Suspend collection If not collected plan to collect in one month.
Inter-regimen	Collect if possible. Research: Ship formalin to I-SPY lab, store frozen. Clinical: submit to local histology Cannot be collected at later date. If not collected complete CRF.	Collect if staff available to process and freeze. Store onsite, do not ship. Plan to collect in one month. If not collected complete CRF.	Suspend collection If not collected plan to collect in one month.
Pre- Surgery/Surgery	Collect if possible. Ship formalin to I-SPY lab, store frozen. If not collected complete CRF & request diagnostic specimen	Collect if staff available to process and freeze. Store onsite, do not ship. If not collected complete CRF.	Suspend collection Note as not collected on CRF if other blood are collected.
Post surgery and annual follow up	n/a	Plan to collect in one month	n/a

I-SPY 2 Site Update

- Site Survey in progress to document site processes.
- Team will update the following slides as new information is made available.

I-SPY 2 A22 Sites Activated

	A22 Date					
Site	Activated	A22 IRB Status	S	R	SF	COVID-19 Status
						Stopped screening patients per response to COVID-19; trouble to collect research biopsies, IR and others are limiting biopsies. MRI breasts are also
UCD	2/12/2020	IRB Approved 22Jan2020	0	1	1	in short supply
Moffitt	2/18/2020	IRB Approved 07Feb2020	3	1	2	
UCHI	2/12/2020	IRB Approved 11Feb2020	2	1	1	
		IRB Approved				Site coordinators not allowed in patient areas; shifting work to those who are on floor
UCSF	2/14/2020	13Feb2020	7	3	2	Backlog at IRB (still need to approve FDA revised Cemiplimab ICFs)
UCSD	2/18/2020	IRB Approved 11Feb2020	4	3	2	
Loyola	2/12/2020	IRB Approved 19Feb2020	2	2	0	Continuing to screen and enroll (I-SPY considered therapeutic trial with IRB)
Mayo MN	2/27/2020	IRB Approved 20Feb2020	1	2	1	
UPenn	3/3/2020	IRB Approved 20Feb2020	0	0	0	
UAB	2/26/2020	IRB Approved 22Feb2020	3	0	0	
Yale	3/4/2020	IRB Approved 17Feb2020	0	0	0	
USC	3/4/2020	IRB Approved 27Feb2020	0	0	0	
Wake Forest	3/6/2020	IRB Approved 27Feb2020	2	0	0	Difficulty accessing EHR from home and redacting source, developing work around
Gtown	3/10/2020	IRB Approved 09Mar2020	1	0	0	

^{© 2020} Quantum Leap Healthcare Collaborative™. Confidential and Proprietary. All rights reserved.

I-SPY 2 A22 Sites NOT Activated

	A22 Date			
Site	Activated	A22 IRB Status	A22 Comments	COVID-19 Status
Columbia	See Comment	IRB Review 06April2020	Pending IRB approval of changes to several ICFs - site believes IRB review/approval by 4/6/2020	
UMinn	See Comment	IRB Stipulation Response	Received IRB feedback on 3/11/2020 asking for clarification - questions pending I-SPY team response	Stopped screening patients (conserving resources); continuing to follow pts
OHSU	See Comment	IRB Stipulation Response		Biopsies, imaging are being evaluated case by case; Research blood is not collected if considered non-essential
Emory	See Comment	IRB Approved 06Mar2020	Pending Pharmacy Training Checklists, Chem Orders & Seed Supply. Pharmacy meets 3/23 & will complete checklists & orders then.	Not screening patients as a response to COVID-19
UPMC	See Comment	IRB Approved 10Mar2020	Pending IRB approval of changes to Screening ICF - site does not have IRB review date	
Sanford	See Comment	IRB Approved 20Feb2020	Pending Chemo Orders, Seed Supply. Site needs 2nd SIV	
Montefiore	N/A	Not yet submitted to IRB		
Vanderbilt	N/A	ON HOLD	Site will submit A22 & A23, SIV will be on A23 (aiming for remote SIV, if travel ban is lifted)	